[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@ShortShitStocks "$DCTH +25% is not enough. These results are strongly compelling for a new SOC - and as indications expand I expect that to eventually cover the majority of all liver metastases. At Friday close the EV of the company was $320M. -Current annual revenues (4x last Q) $100M -Turning profitable in 2026 -Y/Y revenues doubling -Onboarding new commercial sites at a rapid pace -High barrier to entry even after patent expiry supporting higher valuation multiplier -Clinical trials ongoing to expand to much larger indications *All this before the new compelling clinical data now pushing Hepzato as a new"
X Link @ShortShitStocks 2025-10-18T11:06Z XXX followers, 5863 engagements

"@TOWiU2 FYI my career is in what I can best summarize as atypical-biotech-CMC. Not that you have any reason to trust me but Im not clueless on this topic"
X Link @ShortShitStocks 2025-09-30T15:26Z XXX followers, XX engagements

"@SamuBaaa Thanks. For some reason I thought that was due to a one-off accounting situation but my memory may be off. Either way the point is the company will be earning a lot more in the near future"
X Link @ShortShitStocks 2025-10-18T12:44Z XXX followers, XXX engagements